AU2005274390B2 - Substituted hydantoins - Google Patents
Substituted hydantoins Download PDFInfo
- Publication number
- AU2005274390B2 AU2005274390B2 AU2005274390A AU2005274390A AU2005274390B2 AU 2005274390 B2 AU2005274390 B2 AU 2005274390B2 AU 2005274390 A AU2005274390 A AU 2005274390A AU 2005274390 A AU2005274390 A AU 2005274390A AU 2005274390 B2 AU2005274390 B2 AU 2005274390B2
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- dioxo
- imidazolidin
- thiazol
- butyramide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60217504P | 2004-08-17 | 2004-08-17 | |
| US60/602,175 | 2004-08-17 | ||
| US68299705P | 2005-05-20 | 2005-05-20 | |
| US60/682,997 | 2005-05-20 | ||
| PCT/EP2005/008633 WO2006018188A2 (en) | 2004-08-17 | 2005-08-09 | Substituted hydantoins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005274390A1 AU2005274390A1 (en) | 2006-02-23 |
| AU2005274390B2 true AU2005274390B2 (en) | 2012-01-19 |
Family
ID=35589619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005274390A Ceased AU2005274390B2 (en) | 2004-08-17 | 2005-08-09 | Substituted hydantoins |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7427635B2 (https=) |
| EP (1) | EP1781649B1 (https=) |
| JP (1) | JP4927733B2 (https=) |
| KR (2) | KR20090006885A (https=) |
| AR (1) | AR050297A1 (https=) |
| AT (1) | ATE404556T1 (https=) |
| AU (1) | AU2005274390B2 (https=) |
| BR (1) | BRPI0514515A (https=) |
| CA (1) | CA2576599A1 (https=) |
| DE (1) | DE602005008986D1 (https=) |
| ES (1) | ES2313389T3 (https=) |
| MX (1) | MX2007001846A (https=) |
| PL (1) | PL1781649T3 (https=) |
| RU (1) | RU2383542C2 (https=) |
| TW (1) | TW200621764A (https=) |
| WO (1) | WO2006018188A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200621766A (en) * | 2004-09-17 | 2006-07-01 | Hoffmann La Roche | Substituted hydantoins |
| US7612212B2 (en) * | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| JP2010526848A (ja) * | 2007-05-11 | 2010-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| ATE551336T1 (de) | 2007-08-16 | 2012-04-15 | Hoffmann La Roche | Substituierte hydantoine |
| JP2011506533A (ja) | 2007-12-20 | 2011-03-03 | エフ.ホフマン−ラ ロシュ アーゲー | Mekキナーゼ阻害剤としての置換ヒダントイン |
| MX2010014066A (es) * | 2008-06-16 | 2011-06-01 | Univ Tennessee Res Foundation | Compuestos para el tratamiento del cancer. |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| TW201113280A (en) * | 2009-07-03 | 2011-04-16 | Nensius Res As | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS |
| ES2576061T3 (es) | 2010-02-25 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| BR112012022801B8 (pt) | 2010-03-09 | 2019-10-29 | Dana Farber Cancer Inst Inc | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer |
| JP5960683B2 (ja) | 2010-04-28 | 2016-08-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 殺真菌剤としてのケトヘテロアリールピペリジンおよび−ピペラジン誘導体 |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| JP7235859B2 (ja) * | 2018-09-17 | 2023-03-08 | ユンジン ファーム.カンパニー、リミテッド | 新規なチアゾール誘導体及びその薬学的に許容される塩 |
| EP4119556A1 (en) * | 2020-03-13 | 2023-01-18 | Yungjin Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating cancer comprising azole derivatives or pharmaceutically acceptable salt thereof |
| WO2021182914A1 (ko) * | 2020-03-13 | 2021-09-16 | 영진약품 주식회사 | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 |
| KR20210146144A (ko) | 2020-05-26 | 2021-12-03 | 엘지전자 주식회사 | 카트부 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| WO2001083478A2 (en) * | 2000-05-03 | 2001-11-08 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
| WO2003008365A2 (en) * | 2001-07-19 | 2003-01-30 | Pharmacia Italia S.P.A. | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
-
2005
- 2005-08-09 BR BRPI0514515-5A patent/BRPI0514515A/pt not_active IP Right Cessation
- 2005-08-09 KR KR1020087032084A patent/KR20090006885A/ko not_active Ceased
- 2005-08-09 PL PL05771890T patent/PL1781649T3/pl unknown
- 2005-08-09 CA CA002576599A patent/CA2576599A1/en not_active Abandoned
- 2005-08-09 AT AT05771890T patent/ATE404556T1/de active
- 2005-08-09 EP EP05771890A patent/EP1781649B1/en not_active Expired - Lifetime
- 2005-08-09 DE DE602005008986T patent/DE602005008986D1/de not_active Expired - Lifetime
- 2005-08-09 RU RU2007109651/04A patent/RU2383542C2/ru not_active IP Right Cessation
- 2005-08-09 JP JP2007526351A patent/JP4927733B2/ja not_active Expired - Fee Related
- 2005-08-09 KR KR1020077004075A patent/KR100889721B1/ko not_active Expired - Fee Related
- 2005-08-09 MX MX2007001846A patent/MX2007001846A/es active IP Right Grant
- 2005-08-09 AU AU2005274390A patent/AU2005274390B2/en not_active Ceased
- 2005-08-09 WO PCT/EP2005/008633 patent/WO2006018188A2/en not_active Ceased
- 2005-08-09 ES ES05771890T patent/ES2313389T3/es not_active Expired - Lifetime
- 2005-08-11 US US11/202,299 patent/US7427635B2/en not_active Expired - Fee Related
- 2005-08-15 TW TW094127672A patent/TW200621764A/zh unknown
- 2005-08-16 AR ARP050103440A patent/AR050297A1/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| WO2001083478A2 (en) * | 2000-05-03 | 2001-11-08 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
| WO2003008365A2 (en) * | 2001-07-19 | 2003-01-30 | Pharmacia Italia S.P.A. | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100889721B1 (ko) | 2009-03-23 |
| AR050297A1 (es) | 2006-10-11 |
| WO2006018188A2 (en) | 2006-02-23 |
| ATE404556T1 (de) | 2008-08-15 |
| WO2006018188A3 (en) | 2006-05-18 |
| CA2576599A1 (en) | 2006-02-23 |
| EP1781649A2 (en) | 2007-05-09 |
| RU2383542C2 (ru) | 2010-03-10 |
| KR20090006885A (ko) | 2009-01-15 |
| MX2007001846A (es) | 2007-03-28 |
| BRPI0514515A (pt) | 2008-06-10 |
| AU2005274390A1 (en) | 2006-02-23 |
| US20060041146A1 (en) | 2006-02-23 |
| JP4927733B2 (ja) | 2012-05-09 |
| EP1781649B1 (en) | 2008-08-13 |
| DE602005008986D1 (de) | 2008-09-25 |
| PL1781649T3 (pl) | 2009-01-30 |
| TW200621764A (en) | 2006-07-01 |
| ES2313389T3 (es) | 2009-03-01 |
| RU2007109651A (ru) | 2008-09-27 |
| KR20070034635A (ko) | 2007-03-28 |
| US7427635B2 (en) | 2008-09-23 |
| JP2008509950A (ja) | 2008-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005274390B2 (en) | Substituted hydantoins | |
| EP1989186B1 (en) | Hydantoin based kinase inhibitors | |
| KR100869681B1 (ko) | 암 치료를 위한 치환된 히단토인 | |
| US6376491B1 (en) | Bicyclic compounds | |
| US20200216435A1 (en) | Bicyclic heteroaromatic amide compounds for use in therapy | |
| US20200223837A1 (en) | Benzofuran amides and heteroaromatic analogues thereof for use in therapy | |
| KR20100086503A (ko) | Mek 키나아제 저해제로서의 치환된 히단토인 | |
| CN101823987A (zh) | 一类新的dpp-ⅳ抑制剂及其制备方法和用途 | |
| CN101006085A (zh) | 取代的乙内酰脲类 | |
| CA2277105A1 (en) | C-terminal ketone hydroxamic acid inhibitors of matrix metalloproteinases and tnfa secretion | |
| CN101389609B (zh) | 基于乙内酰脲的激酶抑制剂 | |
| AU2015340584B2 (en) | Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |